As a business specializing in the development and production of genetically diverse libraries, Sloning BioTechnology GmbH offers high quality, innovative, tailored protein engineering solutions to our industrial and biopharmaceutical customers worldwide. Our Slonomics® core technology is a unique DNA engineering platform that uses defined sets of double stranded DNA triplets to precisely introduce the required mutations into any DNA sequence. This multiply validated technology takes a novel approach to enable the realization of highly complex design concepts while at the same time ensuring that libraries generated by Sloning have the very highest standards of reliability.

We harness the capabilities of Slonomics® to synthesize SlonoMax® libraries, SlonoMax® libraries are customized mutant libraries that significantly improve the efficiency of screening for new and improved proteins for therapeutic, enzymatic or technical applications.

In addition, we offer a premium gene synthesis service using Slonomics® for our industrial clients. SlonoGene™ is a tailored service offering gene customization and optimization suited perfectly to the needs of our customers.

Sloning BioTechnology adopts an ethical approach to synthetic biology and is a founder member of the International Association Synthetic Biology (IASB: www.ia-sb.eu) formulating industry standards for biosafety and biosecurity.

Founded in 2001, Sloning is located in Munich, Germany with an international presence that facilitates servicing the biopharmaceutical, industrial biotech, agribiotech, and food industries.